Person: GÜNEŞ, BEGÜM
Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them?
2020-05-11T04:00:00Z, CENGİZ, Fatma Pelin, EMİROĞLU, Nazan, BAHALI, ANIL GÜLSEL, DİZMAN, DİDEM, TAŞLIDERE, NAZAN, MERT, Ömer, Akarslan, Tahsin Cagdas, Gunes, Begum, KÜÇÜK, Özlem Su, ONSUN, Nahide, CENGİZ, FATMA PELIN, EMİROĞLU, NAZAN, BAHALI, ANIL GÜLSEL, DİZMAN, DİDEM, TAŞLIDERE, NAZAN, GÜNEŞ, BEGÜM, MERT, ÖMER, SU KÜÇÜK, ÖZLEM, ONSUN, NAHIDE
Coronavirus disease, first emerged in Wuhan, rapidly spread all over the world since December 2019. There are concerns about elective dermatology appointments and its results. Herein, we aimed to find out which type of dermatologic patients attended to dermatology outpatient clinic. The patients visiting the clinics for elective dermatologic diseases between March 11 and 18, 2020, were included in this study. Their age, sex, diagnosis of disease, requirement for emergent intervention, and their medical records about COVID-19 were obtained. There were 390 patients attending to the dermatology outpatient clinic in this period. The most common disease was acne (N: 94, 24%), only 19% of patients need emergent interventions or dose adjustment. There were 40 (10%) patients over the age of 65. After their visits, five patients were diagnosed as COVID-19 in 2weeks. Dermatologic examinations may be a vector for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission since being closed to the patient. Five of our patients were diagnosed as COVID-19 after their elective visit to hospital. Since the asymptomatic course of some young patients, most of our patients were not screened for COVID-19. Our findings support the concerns of elective physician examinations.
Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID‐19 pandemic: The real‐world experience of a single centre
2020-12-01T00:00:00Z, Onsun, Nahide, Yabanci, Aysegul, GÜNEŞ, BEGÜM
There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long‐term drug survival data (i.e. time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR‐TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36 and 48 weeks, and annually thereafter. The behaviours of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID‐19 pandemic, were also investigated.